Skip to main content

Newton Charles W.

In the past year, 2 open-market sale filings worth $11.2K and no purchases.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$11.2K
2 filings
Net
−$11.2K
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Newton Charles W. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

KROS Keros Therapeutics, Inc.

Director2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 15, 2026 (view filing)Jun 114 daysNewton Charles W.DirectorSSale−550$10.04−$5.52K−4.2%12.7K after10b5-1
Aug 20, 2026 (view filing)4:10 PM ETAug 182 daysNewton Charles W.DirectorSSale−551$10.30−$5.68K−4.4%12.1K after10b5-1

LYEL Lyell Immunopharma, Inc.

Chief Financial Officer3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 18, 2025 (view filing)Mar 171 dayNewton Charles W.Chief Financial OfficerPPurchase+200.0K$0.56+$112.0KNew position200.0K after
Aug 13, 2025 (view filing)Aug 11-122 daysNewton Charles W.Chief Financial OfficerSSale−267$10.43−$2.79K−3.0%8.76K after2 lots
Aug 22, 2025 (view filing)Aug 211 dayNewton Charles W.Chief Financial OfficerSSale−1.45K$10.54−$15.3K−8.7%15.3K after